CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Propolis +2 moredrug
Likely dose
Propolis 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03416127
NCT03416127Phase 2Completed
CompareCT.gov

Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment

University of Guadalajara·interventional·Posted Jan 30, 2018·Updated Nov 7, 2022

In Brief

A Phase 2 clinical trial evaluating Propolis, Metformin, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The aim of this study was to evaluate the effect of propolis or metformin on glycemic control in patients with type 2 diabetes mellitus without pharmacological treatment. All patients received for 12 weeks propolis, metformin or placebo. Fasting serum glucose, 2-h serum glucose after oral glucose tolerance test, glycated hemoglobin A1c, a metabolic profile, areas under the curve of glucose and insulin, insulinogenic index, Stumvoll index, and Matsuda index were measured.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesMexico
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 30, 2018
Enrollment StartJan 30, 2018
Primary CompletionDec 20, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.4 years ago

Interventions

Propolisdrug

Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.

Metformindrug

Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.

Placebodrug

Calcined magnesium, two times per day before break-fast and dinner during 12 weeks.